LEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases ...

LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 for the Treatment of APOE4 Associated Alzheimer’s Disease LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease Initial Phase 1 clinical data expected in 2H 2021 NEW YORK, April 20,...

LEXEO Therapeutics Strengthens Management Team with Key Appointments to Accelerate Development of Clinical-Stage Pipeline NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced the continued expansion of its management team with the appointments of two...

LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed...

LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene...